Management

 

  • Robert F. Johnston, Chairman of the Board
    • Johnston founded Johnston Associates, a venture capital firm, in 1968 to provide seed capital for start-ups emerging in the biotechnology and healthcare fields.
    • During his career, he founded numerous public companies including Sepracor (acquired by Dainippon Sumitomo Pharma Co), Cytogen (acquired by EUSA Pharma), I-STAT (acquired by Abbott), Genex and Envirogen (acquired by Shaw Environmental), and was instrumental in the early formation of many private companies such as Sonomed, Immunicon (acquired by J&J), PharmaStem (formerly Biocyte), Praelux (acquired by Amersham/GE) and Targent (acquired by Spectrum). Mr. Johnston served as CEO of Cytogen and Praelux (formerly SEQ).
    • Additionally, he is a member of the Advisory Council of the Department of Molecular Biology at Princeton University.
    • Johnston received his B.A. from Princeton University and his M.B.A. from New York University.
  • Gur Roshwalb, President, Chief Executive Officer
    • Prior to joining Zywie LLC, Dr. Roshwalb served as the Chief Executive Officer of Akari Therapeutics Plc and Celsus Therapeutics Plc.
    • Before moving to industry, Dr. Roshwalb was a Vice President at Venrock, where he was an investment professional on the healthcare team investing in both private and public companies.
    • Prior to this he was a vice president and equity analyst at Piper Jaffray, publishing research on specialty pharmaceutical companies.
    • Prior to Piper, Dr. Roshwalb was in private practice in New York following residency training in internal medicine at Mount Sinai Medical Center, where he served as Chief Resident.
    • Dr. Roshwalb obtained his medical degree from Albert Einstein College of Medicine of Yeshiva University, his MBA from the NYU Stern School of Business and a B.A. from Columbia University.
  • King C. Lee, Ph.D., R.A.C., Regulatory Consultant
    • Lee is an independent consultant, and most recently the VP of Regulatory/Clinical Affairs for Cornerstone Pharmaceuticals, Inc. Dr. Lee is also an adjunct professor of Quinnipiac University, and has been since 2006.
    • Previously, he was the VP of Regulatory Affairs for Acorda Therapeutics, Inc. and held management positions with ATON Pharma, Inc. (acquired by Merck in 2003), VION Pharmaceuticals, Inc. and Sterling-Winthrop.
    • He has authored and co-authored over 45 publications (scientific and professional papers, books and review articles) and over 45 scientific abstracts.
    • He received his Ph.D. in Pharmacology from the University of Kentucky and is certified by the Regulatory Affairs Professionals Board.